Bio-Rad Q1 Plunges to Loss as Analysts See Downside

Forward-Looking Analysis

Wall Street analysts project Bio-Rad Laboratories will generate $2.6 billion in revenue for 2026, reflecting a modest annual growth rate of 1.84%. This forecasted revenue growth significantly lags behind the US Medical Devices industry average of 7.82% and the broader US market average of 13.77%. Consequently, the top-line performance is viewed as lackluster relative to sector peers.

On the profitability front, earnings per share (EPS) are forecast to reach $9.09 in 2026, representing a substantial year-over-year increase of 55.97%. Analysts anticipate a strong earnings trajectory, with EPS expected to grow at an exceptional compound annual rate of 22.12%. However, this earnings growth rate is still projected to trail the US Medical Devices industry average of 23.31% and the US market average of 32.94%. Total net income for 2026 is estimated at approximately $243.3 million, with a range between $224.2 million and $273.2 million.

Investor sentiment remains cautious, with the consensus analyst rating standing at "Hold." Based on three analysts providing price targets, the average 12-month target is $303.33, implying a potential downside of 6.8% from the current trading price of $325.48. The price target range spans from a low of $290.00 to a high of $320.00. Efficiency metrics present further headwinds; the forecast Return on Equity (ROE) is a weak 4.03%, and Return on Assets (ROA) is estimated at 2.82%, both significantly below their respective industry averages of 17.87% and 14.13%. These metrics suggest limited confidence in the firm's ability to efficiently generate shareholder returns in the near term.

Historical Performance Review

Bio-Rad Laboratories delivered a mixed 2026Q1 report, posting revenue of $592.10 million, slightly above the $589.91 million estimate. Despite top-line stability, profitability suffered severely, with net income plunging to -$527.10 million from $720.00 million in the prior quarter. This decline drove EPS down to -$19.55, a stark contrast to the positive $1.89 EPS recorded previously. Gross profit stood at $309.40 million. The significant drop in net income resulted in a negative earnings surprise of -4.21% against EPS expectations, highlighting substantial margin compression and operational challenges during the first quarter of 2026.

Additional News

Bio-Rad has been actively expanding its product portfolio to drive future growth. In May 2026, the company received MicroVal Validation for its EZ-Check Listeria spp. and Listeria monocytogenes testing kits, strengthening its food science segment. Additionally, Bio-Rad expanded its TrailBlazer Kits for antibody conjugation to StarBright Dyes, enhancing capabilities in flow cytometry and Western blot applications. In April, the company introduced the new PTC Harmony Thermal Cycler line to improve PCR access for academic and biopharma labs. Recent webinars in July highlighted the clinical advantages of Droplet Digital PCR (ddPCR) for detecting low-abundance targets and HPV-associated cancers. Meanwhile, Elliott Management has built a stake in Bio-Rad to push for better performance, though family voting control remains a hurdle. The company also announced participation in upcoming investor conferences and the ADLM 2026 Clinical Lab Expo in Anaheim.

Summary & Outlook

Bio-Rad Laboratories faces a challenging outlook characterized by weak efficiency metrics and sluggish revenue growth. While EPS is forecast to grow rapidly, the company lags industry peers in both revenue expansion and return on equity/assets. The recent Q1 net loss underscores near-term profitability risks, exacerbated by geopolitical disruptions and weak academic demand. With analyst consensus firmly at "Hold" and price targets suggesting downside risk, the stock appears overvalued relative to its fundamental growth trajectory. Investors should remain cautious, as the company’s ability to improve operational efficiency and accelerate top-line growth will be critical to reversing its current underperformance against sector benchmarks.